

## Table of Contents for MTN 002 Study-Specific Procedures Manual

List of Abbreviations and Acronyms  
List of Electronic Resources and Web Sites of Interest  
Overview and Version Control

- 1 Introduction  
Refer to Protocol
- 2 Protocol
- 3 Documentation Requirements
  - 3.1 Essential Documents
  - 3.2 Participant Case History Documents
  - 3.3 Study Product Accountability, Chain of Custody, and Dispensing Documentation
  - 3.4 Record Retention Requirements
- 4 Participant Accrual
  - 4.1 Study Accrual Plan and Site-Specific Accrual Targets
  - 4.2 Screening and Enrollment
- 5 Informed Consent
  - 5.1 Overview of Informed Consent Requirements and Procedures
  - 5.2 Informed Consent for Screening and Enrollment
  - 5.3 Documenting the Informed Consent Process
- 6 Participant Follow Up
  - 6.1 Refer to Protocol and SSP Sections 4 and 7
- 7 Visit checklists
  - 7.1 Use of Checklists
  - 7.2 Sequence of Procedures
- 8 Participant Retention
  - 8.1 Retention Definition
  - 8.2 Retention Requirements
  - 8.3 Retention SOPs
  - 8.4 Obtaining and Updating Locator Information
  - 8.5 Retention Tips
- 9 Study Product Considerations for non-Pharmacy Staff
  - 9.1 Gel Use Instructions
  - 9.2 Ordering of MTN 002 Study Product from the Pharmacy
  - 9.3 Dispensing from the Pharmacy to Research Staff
  - 9.4 Return of Unused Study Gel Supplies
  - 9.5 Product-Related Scenarios
- 10 Clinical Considerations
  - 10.1 Baseline Medical History and Ascertainment of Concomitant Medications

- 10.2 Interval Medical History and Updating of Concomitant Medications
- 10.3 Targeted Physical Exams
- 10.4 Pelvic Exams
- 10.5 Genital Bleeding Assessment
- 10.6 STI/RTI Management
- 10.7 Urinary Tract Infections
- 10.8 Product Use Management
  
- 11 Safety Monitoring and Adverse Event Reporting
  - 11.1 Definitions and General Reporting Guidance
  - 11.2 Adverse Event Terminology
  - 11.3 Adverse Event Severity
  - 11.4 Adverse Event Relationship to Study Product
  - 11.5 Adverse Event Outcomes and Follow-Up Information
  - 11.6 Reporting Recurrent Adverse Events
  - 11.7 Social Harms
  - 11.8 MTN 002 Safety Monitoring, Review, and Oversight
  - 11.9 Safety Distributions from DAIDS
  
- 12 Laboratory Considerations
  - 12.1 Overview and General Guidance
  - 12.2 Specimen Labeling
  - 12.3 Procedures for Specimens that cannot be evaluated
  - 12.4 Use of LDMS
  - 12.5 Urine Testing for Urinalysis, Chlamydia and Gonorrhea
  - 12.6 Blood Testing for HIV, Syphilis, Liver and Renal Function, Blood Tenofovir Levels, and Flow Cytometry
  - 12.7 Testing of Vaginal Specimens
  - 12.8 Testing of Specimens Collected during or after Cesarean Section (Cord Blood, Amniotic Fluid, Placental Tissue, and Endometrial Tissue)
  
- 13 Data Collection
  - 13.1 DataFax Overview
  - 13.2 DataFax Form Completion
  - 13.3 MTN 002 Study-Specific Data Collection Information
  - 13.4 Form Supply and Storage
  - 13.5 Case Report Forms and Form-specific Completion Instructions
  
- 14 Data Communiqués
  
- 15 Study Reporting Plan
  - 15.1 Purpose of Reporting Plan
  - 15.2 Study Reports